BMS Archive

Plant · Scientific monograph

Rhodiola rosea

Golden root / Arctic root

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Stress Response Research, Fatigue & Energy Research, Neurological & Cognitive Research, Inflammatory Pathways

Research overview

Historical use

Rhodiola rosea has been used for centuries in traditional medicine across Siberia, Scandinavia, and the Arctic regions, where it was prescribed to enhance physical endurance, resistance to high-altitude conditions, and mental stamina. Viking warriors reportedly used it to enhance strength and endurance. Soviet military and athletic programmes investigated it extensively from the 1940s onward as a performance-enhancing adaptogen.

Modern research context

Rhodiola rosea is supported by converging evidence for antidepressant, anti-fatigue, and neuroprotective effects. A 2026 review identifies Rhodiola rosea as elevating monoamine concentrations and modulating pathways involved in the stress response, placing it alongside Ginkgo and Ashwagandha as a clinically relevant antidepressant supplement [1]. Clinical and preclinical data support its use for major depressive disorder through multi-targeted monoaminergic and anti-inflammatory mechanisms [2]. A 2025 randomised study demonstrates that Rhodiola rosea supplementation combined with eccentric training produces additive antifatigue and muscle-protective effects, improving endurance performance [6]. Salidroside, its primary bioactive, is under investigation for rheumatoid arthritis due to antioxidant and anti-inflammatory properties [7].

Adverse effects

Generally well tolerated at recommended doses. The most commonly reported side effects include dry mouth, dizziness, agitation, and insomnia when taken late in the day. Stimulant-like effects may exacerbate anxiety at high doses. Product quality is highly variable: rosavin — a key marker compound — was detected in only 9 of 13 commercially tested Rhodiola products, highlighting significant quality control concerns [4].

Contraindications

Avoid concurrent use with MAO inhibitors due to additive monoaminergic stimulation [1, 2]. Caution with antidepressants (SSRIs, SNRIs) given pharmacodynamic overlap. Avoid in bipolar disorder (potential for hypomanic switch). Use caution in patients on CYP450-metabolised drugs given salidroside's documented effect on human CYP450 activity [3]. Avoid in pregnancy and lactation due to insufficient safety data.

Clinical and phytochemical data

Used part

Root and rhizome (standardised extract; markers: rosavins ≥3%, salidroside ≥1%)

Primary active compounds

  • Salidroside (p-hydroxyphenethyl-beta-D-glucoside)

  • Rosavins (rosavin, rosin, rosarin)

  • Tyrosol

  • Triandrin and lotaustralin (phenylpropanoids)

  • Flavonoids (quercetin, kaempferol derivatives)

  • Proanthocyanidins

Mechanism of action

Rhodiola rosea exerts adaptogenic effects primarily through elevation of monoamine neurotransmitter concentrations — serotonin, dopamine, and norepinephrine — and modulation of the HPA (hypothalamic-pituitary-adrenal) axis stress response [1]. Salidroside demonstrates potent antioxidant activity via upregulation of Nrf2/HO-1 pathway, and anti-inflammatory effects through inhibition of NF-κB and reduction of TNF-α and IL-6 cytokine production, with therapeutic implications for rheumatoid arthritis [7]. The extract modulates HIF-1α (hypoxia-inducible factor 1-alpha), contributing to anti-hypoxic and altitude adaptation properties identified across Rhodiola species [4]. Salidroside also inhibits monoamine oxidase A (MAO-A) and MAO-B, potentiating monoaminergic neurotransmission and contributing to antidepressant and anti-fatigue effects [1, 2].

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Oral bioavailability of rosavins and salidroside is limited by aqueous solubility constraints; cyclodextrin/PVP nanofiber formulations have been developed specifically to improve delivery and bioavailability of Rhodiola bioactives [5]. Product variability is clinically significant: rosavin content was undetectable in 4 of 13 commercially available products tested [4], meaning inter-product PK differences may be substantial.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Salidroside and rosavins are distributed to target tissues including the CNS and musculoskeletal system based on preclinical pharmacodynamic evidence and observed anti-fatigue effects in clinical exercise studies [6]. Precise volume of distribution and protein binding in humans have not been characterised.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — A 2026 in vitro study directly investigated the effect of salidroside on metabolic activity of both rat and human cytochrome P450 enzymes, demonstrating measurable modulation of CYP450 activity [3]. The specific isoforms and direction of effect (inhibition vs. induction) and clinical magnitude require interpretation from the primary study data.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Elimination pathways and half-life for salidroside and rosavins in humans have not been formally established in published clinical pharmacokinetic studies. Renal excretion of phase II conjugates is assumed based on structural analogy with related phenylpropanoid glycosides.

Safety and interactions

Drug interactions

CYP450 substrates: Salidroside directly modulates metabolic activity of human and rat cytochrome P450 enzymes in vitro [3]; patients co-administering drugs with narrow therapeutic indices metabolised by CYP450 should be monitored. Antidepressants (MAO inhibitors, SSRIs, SNRIs): Pharmacodynamic interaction risk through shared monoaminergic mechanism; combination with MAO inhibitors is contraindicated due to additive monoamine elevation [1, 2]. Herb-drug interactions pose documented risks in the context of complex pharmacokinetics [2]; full interaction profile has not been characterised clinically.

Toxicity

Rhodiola rosea has a favourable preclinical and clinical safety profile at standardised doses. No serious adverse events are reported in clinical adaptogen trials. The primary safety concern is stimulant-like CNS excitation at high doses (agitation, insomnia). Product adulteration and substitution are documented risks given that rosavin content is absent in a significant proportion of commercial products [4]. LD50 data in humans are not established.

Special precautions

Pregnancy

Insufficient human safety data. Avoid during pregnancy due to potential stimulant and HPA-modulating effects.

Lactation

Excretion into breast milk has not been studied. Avoid during lactation.

Hepatic impairment

CYP450-dependent metabolism expected to be altered in hepatic disease; salidroside modulates CYP450 activity [3]. Use with caution and monitor for altered drug levels of co-administered medications.

Renal impairment

No formal studies in renal impairment. Renal excretion of conjugated metabolites is likely; use caution in severe renal impairment.

Sources and references

  1. [1] - Li X, Li X, Li Y et al., "Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways", Frontiers in Nutrition, 2026, PMID: 41909050
  2. [2] - Bertollo AG, Spohr L, Bearzi AE et al., "Medicinal Plants for Major Depressive Disorder", Brain Sciences, 2026, PMID: 41750223
  3. [3] - Klaskova E, Jurica J, Danek PJ et al., "The effect of salidroside on metabolic activity of rat and human cytochromes P450", Pharmacological Reports, 2026, PMID: 41811662
  4. [4] - Koltun-Jasion M, Czerwiec K, Parzonko A et al., "Comprehensive profiling of Rhodiola rosea roots and products: neuroinflammation modulation", Frontiers in Pharmacology, 2025, PMID: 40672359
  5. [5] - Jaskolski M, Paczkowska-Walendowska M, Rybarczyk Z et al., "Cyclodextrin/PVP-Based Nanofibers with Rhodiola rosea Extract for Improved Bioavailability", Molecules, 2025, PMID: 40871512
  6. [6] - Wang IL, Su Y, Zhang L et al., "Combined Rhodiola rosea and eccentric training boost endurance performance", Frontiers in Physiology, 2025, PMID: 40988719
  7. [7] - Guo J, Jiang S, Liu M et al., "Salidroside: A Potential Drug Candidate to Treat Rheumatoid Arthritis", Molecules, 2025, PMID: 41097287
  8. [8] - Urbanska N, Ashaolu TJ, Mattova S et al., "The Potential of Selected Plants and Their Biologically Active Molecules in Treatment of Depression and Anxiety", International Journal of Molecular Sciences, 2025, PMID: 40076986

Additional source links

Continue browsing